Arthralgia as an adverse event to infliximab: A reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept

Journal of the European Academy of Dermatology and Venereology

Volumn 23, Issue 8, 2009, Pages 968-969

  Moustou, A E ^a   Stratigos, A J ^a   Vergou, T ^a   Gregoriou, S ^a   Georgala, S ^a   Danopoulou, I ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; DOUBLE STRANDED DNA; ETANERCEPT; HISTONE; INFLIXIMAB; RHEUMATOID FACTOR; SINGLE STRANDED DNA;

ADULT; ARTHRALGIA; CASE REPORT; DISEASE SEVERITY; DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRALGIA; ARTHRITIS, PSORIATIC; ARTHRITIS, REACTIVE; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67651154532     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2008.03075.x     Document Type: Letter

References (7)

1. De Bandt M, Sibilia J, Loet X et al. Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005 7 : R545 R551.
2. Stratigos AJ, Antoniou C, Stamathioudaki S et al. Discoid lupus erythematosus-like eruption induced by infliximab. Clin Exp Dermatol 2004 29 : 150 153.
3. Reich K, Nestle OF, Papp K et al. Infliximab induction and maintenance therapy for moderate - to - severe psoriasis: a phase III, multicentre, double - blind trial. Lancet 2005 366 : 1367 1374.
4. Wollina U, Hannsel G, Koch A et al. G. Tumor Necrosis Factor-alpha Inhibitor-Induced Psoriasis or Psoriasiform Exanthemata: First 120 cases from the Literature Including a Series of Six New Patients. Am J Clin Dermatol 2008 9 : 1 14.
5. Hyrich KL, Lunt M, Watson KD et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007 56 : 13 20.
6. Arend WP. The mode of action of cytokine inhibitors. J Rheumatol Suppl 2002 65 : 16 21.
7. Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002 301 : 418 426.